跳至主要内容

Enhancing Pork Quality and Carcass Composition in Growing-Finishing Pigs Through Nutritional Supplementation: A Deep Dive into Creatine Monohydrate and Its Synergistic Combinations

The global demand for high-quality pork continues to rise, driven by consumer preferences for leaner meat with improved tenderness, juiciness, and sensory attributes. In response, the swine industry has sought innovative nutritional strategies to optimize carcass composition and meat quality. Among these, ​creatine monohydrate (CMH)​​ has emerged as a promising feed additive due to its role in energy metabolism and muscle physiology. This blog explores a groundbreaking study investigating the effects of CMH alone and in combination with other bioactive compounds—α-lipoic acid (ALA), taurine (Tau), and L-malic acid (LMA)—on growth performance, carcass traits, and meat quality in growing-finishing pigs.


Background and Significance

The Role of Creatine in Muscle Physiology

Creatine is a naturally occurring compound synthesized in the liver, kidneys, and pancreas from arginine, glycine, and methionine. It serves as a critical energy reservoir in muscle cells, facilitating the rapid regeneration of adenosine triphosphate (ATP) during short-term, high-intensity activities (e.g., muscle contraction). Beyond its direct energetic benefits, creatine:

  • Reduces muscle damage​ by stabilizing cellular membranes and scavenging reactive oxygen species (ROS).
  • Enhances protein synthesis​ by upregulating pathways like the mammalian target of rapamycin (mTOR).
  • Modulates lipid metabolism​ by promoting fatty acid oxidation and reducing adipose tissue deposition.

However, challenges such as ​muscle water retention​ (a side effect of creatine’s osmotic properties) and variable efficacy in livestock systems have limited its widespread adoption in swine nutrition.


Combination Strategies to Optimize Creatine’s Benefits

Recent advancements in nutritional science have focused on ​synergistic combinations​ to amplify creatine’s advantages while mitigating drawbacks:

  1. CMH + α-Lipoic Acid (ALA)​: ALA, a potent antioxidant and cofactor for mitochondrial enzymes, may enhance creatine uptake and fatty acid oxidation.
  2. CMH + Taurine (Tau)​: Tau, a sulfur-containing amino acid, supports bile acid conjugation, antioxidative defenses, and calcium homeostasis.
  3. CMH + L-Malic Acid (LMA)​: LMA, a key intermediate in the tricarboxylic acid (TCA) cycle, could synergize with creatine to enhance aerobic energy production.

This study investigates whether these combinations offer superior outcomes compared to CMH alone in improving pork quality and carcass traits.


Materials and Methods

Experimental Design

A total of ​100 crossbred (Duroc × Landrace × Yorkshire) castrated male pigs​ (initial body weight: 60–70 kg) were randomly assigned to five dietary treatments (20 pigs/group, 1 pig/repeat):

  1. Control Group: Basal diet without additives.
  2. CMH Group: Basal diet + ​0.5 g/kg CMH.
  3. CMH+ALA Group: Basal diet + ​0.5 g/kg CMH + 0.1 g/kg ALA.
  4. CMH+Tau Group: Basal diet + ​0.5 g/kg CMH + 0.1 g/kg Tau.
  5. CMH+LMA Group: Basal diet + ​0.5 g/kg CMH + 0.5 g/kg LMA.

Pigs were housed under standard conditions with ad libitum access to feed and water for ​50 days. Growth performance (average daily gain, feed efficiency) and carcass traits (backfat thickness, loin eye area) were evaluated at slaughter. Meat quality parameters (pH, drip loss, color, shear force) and molecular markers (gene expression, enzyme activity) were analyzed post-mortem.

Sample Collection and Analyses

  • Carcass Traits: Hot carcass weight, dressing percentage, backfat thickness (measured at three points), and loin eye area.
  • Meat Quality: pH at 45 minutes and 24 hours post-mortem, drip loss, cooking loss, press loss, colorimetric values (L*, a*, b*), and Warner-Bratzler shear force.
  • Biochemical Assays: Muscle samples were analyzed for ​creatine, phosphocreatine, glycogen, lactate, and antioxidant capacity using commercial kits.
  • Gene Expression: Relative mRNA levels of CrT (creatine transporter), MyHC (myosin heavy chain isoforms), and MB (myoglobin) were quantified via qRT-PCR.

Results

1. Growth Performance and Carcass Composition

  • Average Daily Gain and Feed Efficiency: No significant differences were observed across groups, indicating that CMH-based supplements did not adversely affect growth rates.
  • Backfat Thickness: All CMH-supplemented groups exhibited ​significantly reduced backfat thickness​ compared to controls (e.g., CMH+LMA group: 1.13 cm vs. control: 2.36 cm; P < 0.05).
  • Loin Eye Area: The CMH+ALA and CMH+LMA groups showed ​increased loin eye area​ (53.96 cm² and 52.88 cm², respectively), suggesting enhanced muscle development.

2. Meat Quality Parameters

  • Drip Loss and Cooking Loss: CMH and CMH+ALA groups demonstrated ​lower drip loss​ (2.32–2.25% vs. control: 2.74%) and ​cooking loss​ (17.36–15.42% vs. control: 14.39%), indicating improved water-holding capacity.
  • Color Stability:
    • CMH+ALA group exhibited higher ​L* (lightness)​​ and ​b* (yellowness)​​ values, reflecting brighter, more yellowish lean meat.
    • Conversely, CMH+Tau group showed reduced a* (redness) values, potentially linked to altered myoglobin oxidation states.
  • Shear Force: No significant differences in tenderness were detected, suggesting minimal impact on post-mortem proteolysis.

3. Energy Metabolism and Antioxidant Status

  • Enzyme Activities:
    • Succinate Dehydrogenase (SDH)​​ and ​Creatine Kinase (CK)​​ activities were significantly elevated in CMH-treated groups, indicating enhanced oxidative phosphorylation and ATP turnover.
    • Total Antioxidant Capacity​ increased by up to 120% in CMH+ALA pigs, highlighting synergistic antioxidant effects.
  • Metabolite Levels:
    • Lactate Accumulation​ was reduced by 44–48% in CMH-fed groups, confirming attenuated glycolytic flux during stress.
    • Phosphocreatine Reserves​ doubled in CMH+ALA pigs, underscoring improved energy buffering capacity.

4. Molecular Mechanisms

  • Gene Expression:
    • CrT​ (creatine transporter) mRNA levels were upregulated 8-fold in CMH-fed pigs and ​25-fold in CMH+ALA pigs, explaining enhanced creatine uptake.
    • Myoglobin (MB)​​ and ​MyHC IIa​ (oxidative fiber marker) expression increased in CMH+ALA pigs, suggesting a shift toward more oxidative muscle fibers.

Discussion

Key Findings

  1. CMH as a Multi-Faceted Nutrient:
    • Reduced backfat thickness likely stems from CMH’s role in ​fatty acid oxidation​ and ​lipid metabolism remodeling.
    • Improved water-holding capacity (via CK/SDH upregulation) and reduced drip loss highlight its functional benefits for meat quality.
  2. Synergistic Effects of Combinations:
    • CMH+ALA: Outperformed other groups in enhancing loin eye area, antioxidative capacity, and oxidative fiber abundance. ALA’s ability to shuttle fatty acids into mitochondria and stabilize cellular membranes may explain these outcomes.
    • CMH+LMA: Showed the greatest reduction in backfat thickness, potentially through synergistic activation of the TCA cycle and enhanced β-oxidation.
  3. Trade-Offs and Limitations:
    • CMH+Tau increased cooking loss and negatively impacted meat color, possibly due to altered calcium homeostasis or methionine displacement.
    • Long-term safety and cost-effectiveness of high-dose CMH supplementation require further investigation.

Implications for the Swine Industry

  • Economic Benefits: Reducing backfat while increasing lean meat yield improves carcass value and profitability.
  • Consumer Appeal: Enhanced meat quality traits (juiciness, color stability) align with market demands for premium pork products.
  • Sustainability: Optimized feed formulations reduce reliance on pharmaceutical growth promoters and lower environmental impacts associated with excess fat deposition.

Conclusion

This study demonstrates that strategic supplementation of CMH, particularly in combination with ALA or LMA, offers a robust framework for improving growth efficiency, carcass composition, and meat quality in finishing pigs. While CMH alone effectively reduces fat accretion and enhances water-holding capacity, synergistic blends unlock additional benefits through metabolic pathway modulation. Future research should focus on optimizing dose ratios, long-term animal health outcomes, and economic feasibility to translate these findings into commercial practice.

Kaifeng Darui Pharmaceutical Co., Ltd.

Kaifeng Darui Pharmaceutical Co., Ltd.

Dedicated to high-end pharmaceutical raw materials, food additives, and intermediates.

About Us

Kaifeng Darui Pharmaceutical Co., Ltd., established on June 19, 2020, with a registered capital of 27 million RMB, is a high-tech enterprise located in the Kaifeng Fine Chemical Industrial Park. We focus on the R&D, production, and sales of high-end pharmaceutical raw materials, food additives, and intermediates.

We are a professional GMP-certified manufacturer of veterinary non-sterile APIs, strictly adhering to veterinary GMP requirements in design and construction. Our facility boasts a clean production environment and a rational layout.

We uphold the concept of green development, emphasizing talent and team building to achieve sustainable and healthy growth.

Financial Highlights:

  • 2023 Total Output Value: 44 million RMB, Tax Contribution: 1.45 million RMB.
  • 2024 Total Output Value: Over 60 million RMB, Tax Contribution: 2 million RMB.

Company Philosophy: "Survive by quality, root in talent; develop by technology, benefit from management." We persistently pursue excellent quality and a perfect brand and corporate image.

Research & Development

Since our inception, we established a dedicated technical team for R&D and technology introduction. Currently, we employ over 100 staff, with more than 20 R&D professionals (over 20% of workforce). Over 70% hold college degrees or higher, including 2 senior engineers, 2 associate professors, 1 lecturer, and 4 intermediate engineers.

We possess an independent R&D center (320 sq meters) with professional chemical laboratories and dedicated testing/analysis units. Our equipment includes HPLC, GC, UV-Vis Spectrophotometers, analytical balances, moisture analyzers, etc.

We collaborate closely with domestic universities and research institutions like Henan Academy of Sciences Chemical Research Institute Co., Ltd., Pingdingshan University, and Xinxiang Medical University to foster industry-university-research cooperation.

Facilities

Our plant is designed and built according to "Veterinary Drug Manufacturing Quality Management Standards".

  • Non-sterile API workshop (700 sq meters) with synthesis and refining/drying/packaging sections.
  • Two production lines with separate air purification systems; clean areas meet Class D standards.
  • Standardized production workshops, distillation equipment, 150 t/d wastewater treatment facility, and RCO exhaust gas treatment unit.
  • Water production equipment and air conditioning/purification systems.
  • Warehousing: Raw/auxiliary material, finished product, packaging material, and special management finished product warehouses.

Qualifications & Honors

  • High-tech Enterprise Certification (2023).
  • Henan Province Innovative Small and Medium-sized Enterprise (Dec 2022).
  • Kaifeng City Alkane Bromination Product Engineering Technology Research Center (2023).
  • Loving Charity Enterprise Title (Jan 2023).
  • Kaifeng Pharmaceutical Industry Association Council Member (Since 2021), Chairman Yang Xiaoke appointed as Council Director (Jan 2024).
  • Veterinary Drug Production License and 18 API GMP Certificates from Henan Provincial Department of Agriculture and Rural Affairs (Nov 2024).

Intellectual Property

We emphasize technological innovation and transformation. As of the report date, we hold 12 utility model patents, with 4 applications pending. These patents enhance our independent innovation capabilities and promote the transformation of scientific achievements.

Products & Services / Cooperation

Focus Areas:

  • Fine Chemicals & APIs
  • Food Additives
  • Fine Chemical & Pharmaceutical Intermediates

Areas for Cooperation:

  • Development of new veterinary and pet APIs.
  • Development of new food additives.
  • Cooperation on key production technologies, development and application of fine chemicals and pharmaceutical intermediates.

Future Outlook & Industry Prospects

As a certified High-tech Enterprise, we aim to standardize R&D project management, enhance innovation, and follow the growth path of quality SMEs (Sci-tech SME, Innovative SME, "Specialized, Refined, Unique, New" SME, Sci-tech Little Giant).

Key Development Directions:

  • Leveraging alkane bromination technology, establishing a national-level R&D, demonstration, training, pilot testing, and cooperation base.
  • Strengthening high-value-added biomedical fine products based on existing antiviral and anthelmintic products through R&D and university collaborations.
  • Continuing focus on veterinary APIs, capitalizing on the growing pet market, expanding livestock farming needs, and increasing international competitiveness and export opportunities for Chinese veterinary APIs.

Three-Year Goal (Targeting 2025): Achieve 100 million RMB in production and sales value, increase R&D investment to 20 million RMB, develop 2-3 new products annually, and attain the "Specialized, Refined, Unique, New" enterprise status.

© Kaifeng Darui Pharmaceutical Co., Ltd. All rights reserved.

Contact Us

Address: Kaifeng Fine Chemical Park, Henan, China

Tel: +86-13837178289

Email: [email protected]